FDA Holds Hearing on Jet Lag Sleep Drug
Published Date: 6/3/2026
Notice
Summary
Vanda Pharmaceuticals asked the FDA to approve a new use for their sleep drug HETLIOZ to treat jet lag, but the FDA said no and now there’s a public hearing to decide what’s next. This affects Vanda, travelers hoping for a jet lag fix, and could delay the drug’s availability while money and time are on the line. The hearing starts July 20, 2026, so mark your calendars!
No Economic Impacts Identified for this Document
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-14073 — Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047 — Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-14779 — Determination That RASUVO (Methotrexate) Solution, 27.5 Milligrams/0.55 Milliliter (27.5 Milligrams/0.55 Milliliter), Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The FDA has decided that RASUVO (methotrexate) solution wasn’t taken off the market because of safety or effectiveness problems. This means generic drug makers can now apply to sell their own versions, making it easier and possibly cheaper for patients who need this medicine. If all rules are met, these generics could hit the market soon, helping more people get access without breaking the bank.
2026-14573 — Food Standards of Identity Modernization; Pasteurized Orange Juice
The FDA is updating the rules for pasteurized orange juice by lowering the minimum sugar content and allowing up to 15% of a new type of citrus juice. This change helps juice makers, especially in Florida, keep up with modern practices without raising costs. The new rules kick in on August 19, 2026, giving producers time to adjust.
2026-14438 — Agency Information Collection Activities; Proposed Collection; Comment Request; Infant Formula Requirements
The FDA wants your thoughts on how they collect info about infant formula rules, like labeling, quality checks, and recordkeeping. This affects infant formula makers who must follow these rules and use a new electronic form to report info. You’ve got until September 15, 2026, to share your comments—no cost changes yet, just a chance to improve how info is gathered!
2026-14441 — Agency Information Collection Activities; Proposed Collection; Comment Request; Accreditation Scheme for Conformity Assessment Program
The FDA wants your thoughts on a plan to improve how they check if medical products meet safety rules. This affects companies making medical devices and could change how they prove their products are safe. You’ve got until September 15, 2026, to share your ideas—no cost changes yet, just a chance to help shape the process!
Previous / Next Documents
Previous: 2026-11045 — Submission for OMB Review; 30-Day Comment Request Regular Clearance for the National Institute of Mental Health Data Archive (NDA), (NIMH)
The National Institute of Mental Health (NIMH) is asking for a 30-day public comment period to review and approve their data collection process for the Mental Health Data Archive. This affects researchers and anyone who shares mental health data with NIMH. Comments are due by June 3, 2026, and there’s no new cost involved—just keeping things clear and up-to-date!
Next: 2026-11050 — Notice on Penalty Inflation Adjustments for Civil Monetary Penalties
The Social Security Administration is keeping civil monetary penalties (fines) at the same 2025 levels through January 14, 2027. This means anyone who might face these fines won’t see increases for now, even though they usually adjust for inflation every year. So, if you’re involved with Social Security rules, the penalty amounts won’t change for a while.